The Seraph®-100 Microbind Affinity Blood Filter Does Not Affect Vancomycin, Tacrolimus, and Mycophenolic Acid Plasma Concentrations

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)
35 Downloads (Pure)

Abstract

Extracorporeal blood purification is considered an adjunct therapy in critically ill patients with life-threatening conditions such as sepsis and septic shock. It consists of cytokine removal, removal of endotoxins, a combination of both, or the removal of pathogens themselves. The latter technique was introduced for clinical application very recently. This case study describes a case of a 69-year-old female lung transplant recipient patient with a persistent VV-ECMO-related septic deep vein thrombosis with continuous renal replacement therapy-dependent acute kidney injury initiated on the Seraph®-100 Microbind Affinity Filter in order to control the persistent bacteraemia with coagulase-negative staphylococci. Drug plasma concentrations (vancomycin, tacrolimus, and mycophenolic acid) were measured before and after the device to calculate absorber-related drug clearance.

Original languageEnglish
Pages (from-to)971-975
Number of pages5
JournalBlood Purification
Volume50
Issue number6
DOIs
Publication statusPublished - 1 Sept 2021

Bibliographical note

Publisher Copyright:
© 2021 The Author(s). Published by S. Karger AG, Basel.

Fingerprint

Dive into the research topics of 'The Seraph®-100 Microbind Affinity Blood Filter Does Not Affect Vancomycin, Tacrolimus, and Mycophenolic Acid Plasma Concentrations'. Together they form a unique fingerprint.

Cite this